VivoSeq
Other

Heterotopic Ossification

0

Pipeline Programs↗

1

Active Trials↗

0

Companies Involved↗

Heterotopic Ossification is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

67/100

Attrition Rate

17/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

6

clinical trials

Unknown status2 · 33%
Completed2 · 33%
Withdrawn1 · 17%
Recruiting1 · 17%

Clinical Trials

Trial Activity

6 trials

Continuous Passive Motion Versus Heterotopic Ossification
Recruiting·UUniversity of Ioannina·N/A·NCT05906056·20 enrolled
Prevention of Heterotopic Ossification With Arcoxia After Total Hip Replacement
Completed·RRadboud University Medical Center·Phase 4·NCT01022190·42 enrolled
Tranexamic Acid Prophylaxis for Heterotopic Ossification in Elbow Fracture-Dislocation Surgery
Completed·—·N/A·NCT06088407·50 enrolled
Study of Pamidronate for the Prevention of Heterotopic Ossification
Withdrawn·UUniversity Hospital, Basel, Switzerland·N/A·NCT00262392
Indomethacin Prophylaxis for Heterotopic Ossification After Surgical Treatment of Elbow Trauma
Unknown status·LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's·N/A·NCT01744314·150 enrolled
Celecoxib for Primary Prophylaxis of Combat-Related Heterotopic Ossification
Unknown status·WWalter Reed National Military Medical Center·N/A·NCT01631669·100 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)